Invokana Dosage

Generic name: canagliflozin 100mg
Dosage form: tablet, film coated
Drug class: SGLT-2 inhibitors

Medically reviewed by Drugs.com. Last updated on Apr 30, 2021.

Prior to Initiation of INVOKANA

Assess renal function before initiating INVOKANA and as clinically indicated [see Warnings and Precautions (5.2)].

In patients with volume depletion, correct this condition before initiating INVOKANA [see Warnings and Precautions (5.2), Use in Specific Populations (8.5, 8.6)].

Recommended Dosage

See Table 1 for dosage recommendations based on estimated glomerular filtration rate (eGFR).

Table 1: Recommended Dosage
estimated glomerular filtration rate eGFR (mL/min/1.73 m2)	Recommended Dosage
eGFR 60 or greater	100 mg orally once daily, taken before the first meal of the day. Dose can be increased to 300 mg once daily for additional glycemic control.
eGFR 30 to less than 60	100 mg once daily.
eGFR less than 30	Initiation is not recommended, however patients with albuminuria greater than 300 mg/day may continue 100 mg once daily to reduce the risk of ESKD, doubling of serum creatinine, CV death, and hospitalization for heart failure [see Indications and Usage (1), Use in Specific Populations (8.6)].
On dialysis	Contraindicated [see Contraindications (4)].

Concomitant Use with UDP-Glucuronosyl Transferase (UGT) Enzyme Inducers

Patients with eGFR 60 mL/min/1.73 m2 or greater

If an inducer of UGTs (e.g., rifampin, phenytoin, phenobarbital, ritonavir) is co-administered with INVOKANA, increase the dose to 200 mg (taken as two 100 mg tablets) once daily in patients currently tolerating INVOKANA 100 mg. The dose may be increased to 300 mg once daily in patients currently tolerating INVOKANA 200 mg and who require additional glycemic control [see Drug Interactions (7.1)].

Patients with eGFR less than 60 mL/min/1.73 m2

If an inducer of UGTs (e.g., rifampin, phenytoin, phenobarbital, ritonavir) is co-administered with INVOKANA, increase the dose to 200 mg (taken as two 100 mg tablets) once daily in patients currently tolerating INVOKANA 100 mg. Consider adding another antihyperglycemic agent in patients who require additional glycemic control.